Dr Reddy’s launches Hervycta to treat cancer in India
Team Udayavani, Jul 26, 2018, 12:00 PM IST
New Delhi: Drug major Dr Reddy’s Laboratories (DRL) today announced the launch of Hervycta, indicated for the treatment of certain types of cancer, in India.
Hervycta (Trastuzumab), a biosimilar of Roche’s Herceptin in India, is used for treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer).
Hervycta is available in strengths of 150 mg and 440 mg multiple dose vials, the company said in a regulatory filing.
“We strive every day to do what matters most for patients. Hervycta is a step forward in our effort to accelerate access to cancer patients in India, in the Oncology biosimilar space,” Dr Reddy’s Laboratories CEO-Branded Markets (India and Emerging Markets) MV Ramana said.
Quoting Ipsos data, the company said the Herceptin and its biosimilars had India sales of Rs 290 crore for the most recent 12 months ending in December 2017.
Dr Reddy’s currently has four biosimilar products commercialised in India and various emerging markets, and an active pipeline of several biosimilar products in the oncology and immunology space.
DRL shares were trading 1.01 per cent up at Rs 2,110 apiece on the BSE.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Study links overthinking to ‘constant communication’ between brain’s fear-centre, social behaviour
Mangaluru: Campco opposes WHO’s claim of arecanut being carcinogenic
10 month baby gets new heart, new life
World COPD Day: Know your lung function
As Delhi chokes with dangerous pollution levels, doctors warn of health risks for all
MUST WATCH
Latest Additions
Battle royal at Udaipur palace after BJP’s Vishvaraj Singh denied entry over family feud
5 killed as lorry runs over people sleeping on roadside in Kerala’s Thrissur
Cabinet expansion in Karnataka? Aspirants lobby intensely
RBI Governor Shaktikanta Das hospitalised
Will impose 25 per cent tariff on all imports from Canada, Mexico: Trump
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.